Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
Authors
Keywords
-
Journal
JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-15
DOI
10.1007/s00415-020-10074-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes
- (2019) Hajime Yano et al. Multiple Sclerosis and Related Disorders
- To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis
- (2019) Gabriel Bsteh et al. Multiple Sclerosis and Related Disorders
- ‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis?
- (2018) H. Hegen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
- (2018) Ilya Kister et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES
- (2017) Ilya Kister Multiple Sclerosis Journal
- Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – NO
- (2017) W Oliver Tobin et al. Multiple Sclerosis Journal
- Epidemiology of Multiple Sclerosis in Austria
- (2017) Sabine Salhofer-Polanyi et al. NEUROEPIDEMIOLOGY
- Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES
- (2017) Ilya Kister Multiple Sclerosis Journal
- Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – NO
- (2017) W Oliver Tobin et al. Multiple Sclerosis Journal
- Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
- (2016) Ilya Kister et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors
- (2016) Gabriel Bsteh et al. Multiple Sclerosis Journal
- The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
- (2016) Ludwig Kappos et al. NEUROLOGY
- Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors
- (2016) Gabriel Bsteh et al. Multiple Sclerosis Journal
- Cerebrospinal fluid and urinary biomarkers in multiple sclerosis
- (2013) R. Dobson et al. ACTA NEUROLOGICA SCANDINAVICA
- Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
- (2012) M. Tutuncu et al. Multiple Sclerosis Journal
- Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
- (2011) Giancarlo Comi et al. LANCET NEUROLOGY
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
- (2008) L. K. Fisniku et al. BRAIN
- Relapses in multiple sclerosis are age- and time-dependent
- (2008) H Tremlett et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Natural history of secondary-progressive multiple sclerosis
- (2008) Helen Tremlett et al. Multiple Sclerosis Journal
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started